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Table 1
Predictor End of treatment WOMAC pain
(negative values indicating a decrease
in pain)
Active treatment (control as reference) -0.86
(95% conﬁdence interval) p-value (-1.74, 0.01) 0.05
Baseline WOMAC pain score 0.38
(95% conﬁdence interval) p-value (0.19, 0.57) 0.0002
Treatment, period 1 vs. period 2 -0.04
(95% conﬁdence interval) p-value (-0.92, 0.84) 0.93
After removing the potential for carryover effect, the model demon-
strated that the mean difference in pain between the active and
control treatments was -0.86 units (95% conﬁdence interval 1.74,
0.01 [p=0.05]) on the WOMAC pain scale (range 0-20), indicating
a small decrease in pain in association with the multi-modal active
treatment.
Conclusions: The effects of multi-modal realignment therapy on
pain and function in persons with medial tibiofemoral OA are small
and of equivocal clinical and statistical signiﬁcance.
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Purpose: Gel-200 is a new cross-linked HA gel. This was a
multi-center, randomized controlled trial to determine if a single
intraarticular (IA) injection of Gel-200 is superior to phosphate
buffered saline (PBS) in treatment of symptomatic knee OA.
Methods: To test for superiority of Gel-200 vs PBS by WOMAC
Pain in patient with symptomatic knee OA, with WOMAC VAS
Pain scores at baseline ≥40 mm in affected and ≤20 mm in con-
tralateral knees; secondary analyses included OMERACT/OARSI
responses, TOTAL WOMAC and Physical Function scores, subject
and physician global evaluations of disease activity. Subjects re-
ceived Gel-200 or PBS 1-2 weeks after screening with evaluations
Weeks 1, 3, 6, 9, and 13.
Results: 375 comprised intent to treat [ITT]: 247 Gel 200 vs 128
PBS; and 229 vs 115 per protocol [PP] populations. Subjects had
a mean age 60.5 years; 59.6% were women, 92.2% Caucasian
with mean disease duration of 2.5-3.4 years. Treatment groups
were imbalanced at screening with statistically higher WOMAC
Pain: 69.1 vs 65.4, p<0.01 and TOTAL WOMAC scores: 68.0 vs
64.3, p<0.05; in Gel-200 vs PBS, respectively. Effectiveness of
a single intraarticular injection of Gel-200 was rapid and durable,
with statistical signiﬁcance in WOMAC Pain scores for duration
of effectiveness across Weeks 1 - 13 in ITT and PP populations;
supported by secondary endpoints [Table 1]. In the safety popu-
lation [n=377] incidence of adverse events [AEs] within 24 hours
of study injection with Gel-200 were comparable with PBS [Table
1]. No allergic reactions or unanticipated device-related AEs were
reported. Serious AEs occurred in 8 subjects; including 4 can-
cers; all receiving Gel-200, none related to study injection without
evidence to support a causal relationship.
Conclusions: The effectiveness of a single injection of Gel-200
was rapid and durable, with statistical signiﬁcance in WOMAC
Pain, supported by secondary outcome measures. The low inci-
dence of AEs within 24 hours of injection and absence of allergic
Table 1. Effectiveness and Safety Outcomes
Outcome Measures Gel-200 Advantage vs p value
[ITT, n=375] [PP, n=344] PBS Weeks 1-13
WOMAC Pain (ITT) 4.99 0.048
WOMAC Pain (PP) 6.25 0.020
Strict OMERACT/OARSI Responses (ITT) 0.47 0.022
Strict OMERACT/OARSI Responses (PP) 0.55 0.012
Outcome Measures Gel-200 Advantage vs 13 p value
[PP, n=344] PBS at Week 13
WOMAC Pain 7.26 0.019
TOTAL WOMAC 6.52 0.035
WOMAC Physical Function 6.38 0.040
OMERACT/OARSI Responders 60.5% vs 51.5% 0.012
Strict OMERACT/OARSI Responders 45.9% vs 35.6% 0.022
Adverse Events: N (%) subjects Gel-200 vs PBS[Safety, n=377]
Joint swelling 35 (14.1)/15 (11.7)
Joint effusion 28 (11.2)/13 (10.2)
Arthralgia 19 (7.6)/12 (9.4)
reactions or ‘pseudosepsis’ support its favorable safety proﬁle in
treatment of symptomatic OA of the knee.
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Purpose: To evaluate the impact of treatment of a natural multi-
mineral supplement from seaweed (Aquamin™) on walking dis-
tance, pain and joint mobility in subjects with moderate to severe
osteoarthritis of the knee.
Methods: Subjects (n = 70) with moderate to severe osteoarthritis
of the knee were randomized to four double-blinded treatments
for 12 weeks: (a) Glucosamine sulfate (1500 mg/d); (b) Aquamin
(2400 mg/d); (c) Combined treatment composed of Glucosamine
sulfate (1500 mg/d) plus Aquamin (2400 mg/d) and (d) Placebo.
Primary outcome measures were WOMAC scores and 6 Minute
Walking Distances (6 MWD).
Results: Fifty subjects completed the study and analysis of
the data showed signiﬁcant differences between the groups for
changes in WOMAC pain scores over time (p = 0.009 ANCOVA);
Only the Aquamin and Glucosamine groups demonstrated signif-
icant improvements in symptoms over the course of the study.
Within group analysis demonstrated signiﬁcant improvements over
time on treatment for the WOMAC pain, activity, composite and
stiffness (Aquamin only) scores as well as the 6 minute walking
distances for subjects in the Aquamin and Glucosamine treatment
groups. The Aquamin and Glucosamine groups walked 101 feet
(+7%) and 56 feet (+3.5%) extra respectively. All treatments were
well tolerated and the adverse events proﬁles were not signiﬁcantly
different between the groups.
Conclusions: This study suggested that the multi mineral supple-
ment, Aquamin, may reduce the pain and stiffness of osteoarthritis
of the knee over 12 weeks of treatment.
